WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 20, 2012--
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science, today announced that it has appointed David M. Sabatini, MD,
PhD, to its Scientific Advisory Board. The Board was formed in 2010 to
formalize the two-way exchange of technological information between the
company and representatives from some of the world’s premiere centers of
health, science and education.
Dr.
Sabatini is a member of the Whitehead Institute for Biomedical
Research, where he studies the basic mechanisms of cell growth. He has
several affiliations with the Massachusetts Institute of Technology
(MIT), serving as senior associate member of The Broad Institute, member
of the David H. Koch Institute for Integrative Cancer Research, as well
as associate professor of biology. He is also an investigator at the
Howard Hughes Medical Institute. Dr. Sabatini received his doctorate
degrees from Johns Hopkins University in 1997 and has been awarded
numerous academic distinctions.
“We are pleased to add David’s insight as a leading life sciences
researcher to our Scientific Advisory Board,” said Marc N. Casper,
president and chief executive officer of Thermo Fisher Scientific. “The
Board plays an important role in helping us to set a course for
innovation that creates value for our customers, and his extensive work
in understanding how cells function and metabolize plays a key role in
the development of new treatments for disease.”
The Scientific Advisory Board includes R&D leaders from across Thermo
Fisher, as well as the following external members:
-
Tyler
Jacks, PhD, member of Thermo Fisher’s board of directors, David H.
Koch professor of biology and director of the David H. Koch Institute
for Integrative Cancer Research at MIT, and investigator at the Howard
Hughes Medical Institute
-
Ronald
W. Davis, Stanford University, Department of Biochemistry
-
Steven
P. Gygi, PhD, Harvard Medical School, Department of Cell Biology
-
William
C. Hahn, MD, PhD, Dana-Farber Cancer Institute, Department of
Medical Oncology
-
David
R. Hillyard, MD, University of Utah, Department of Pathology.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science. Our mission is to enable our customers to make the world
healthier, cleaner and safer. With revenues of $12 billion, we have
approximately 39,000 employees and serve customers within pharmaceutical
and biotech companies, hospitals and clinical diagnostic labs,
universities, research institutions and government agencies, as well as
in environmental and process control industries. We create value for our
key stakeholders through three premier brands, Thermo Scientific, Fisher
Scientific and Unity™ Lab Services, which offer a unique combination of
innovative technologies, convenient purchasing options and a single
solution for laboratory operations management. Our products and services
help our customers solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
Source: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron
O’Brien, 781-622-1242
ron.obrien@thermofisher.com
www.thermofisher.com
or
Investor
Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
